Anti-IL-17A antibody-associated de novo vitiligo: Case report and review of literature

Interleukin (IL)-17 inhibitor is a biological therapy approved for moderate to severe psoriasis and psoriatic arthritis. The common adverse events of IL-17 inhibitor include injection site reaction, infections, nasopharyngitis, and headache. However, vitiligo associated with the use of IL-17 inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Hsing-Jou, Chan, Yu-Pei, Shen, Peng-Chieh, Ku, Cheng-Lung, Ng, Chau Yee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889818/
https://www.ncbi.nlm.nih.gov/pubmed/36741377
http://dx.doi.org/10.3389/fimmu.2022.1077681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889818/
https://www.ncbi.nlm.nih.gov/pubmed/36741377
http://dx.doi.org/10.3389/fimmu.2022.1077681

Ejemplares similares